Remove 2014 Remove Drug Pricing Remove Vaccines
article thumbnail

The unsustainability of clinical trials and need for transformative change

Pharmaceutical Technology

How will RFK Jr’s American dream for vaccines play out? According to a November 2024 GlobalData report, per-trial costs have risen steadily since 2014, with single country trials increasing by 2.9% 10 “That is simply unsustainable,” Kent Thoelke argues, especially as drug pricing pressures mount in major markets.

article thumbnail

Incyte replaces CEO Hoppenot with dealmaker Meury

BioPharma Dive

The company now owns six other approved drugs, including a cream formulation of Jakafi’s main ingredient that’s proved useful treating atopic dermatitis and vitiligo. Hervé joined Incyte in 2014 when it was a single product, U.S.-only says US won’t donate to global vaccine effort View all Events 07 JUL Webinar | 10 a.m.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Pricing, Profits and Progress: Pharma’s Post-COVID Priorities

pharmaphorum

The need for firms to make a reasonable profit is paramount in today’s world; healthy pharmaceutical research and manufacturing are the keys to ending disease, curing chronic conditions, and discovering new therapies and vaccines that address the latest medical challenges. The Big Misconception. Is the Middleman at Fault?

article thumbnail

The golden era of GLP-1 drugs: How will it impact medicine and society?

BioPharma Dive

Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy An article from Sponsored The golden era of GLP-1 drugs: How will it impact medicine and society? You can unsubscribe at anytime. The implications of this shift are profound.